Skip to Content
Merck
CN
  • Mechanism and fitness costs of PR-39 resistance in Salmonella enterica serovar Typhimurium LT2.

Mechanism and fitness costs of PR-39 resistance in Salmonella enterica serovar Typhimurium LT2.

Antimicrobial agents and chemotherapy (2008-06-04)
Maria Pränting, Aurel Negrea, Mikael Rhen, Dan I Andersson
ABSTRACT

PR-39 is a porcine antimicrobial peptide that kills bacteria with a mechanism that does not involve cell lysis. Here, we demonstrate that Salmonella enterica serovar Typhimurium can rapidly acquire mutations that reduce susceptibility to PR-39. Resistant mutants appeared at a rate of 0.4 x 10(-6) per cell per generation. These mutants were about four times more resistant than the wild type and showed a greatly reduced rate of killing. Genetic analysis revealed mutations in the putative transport protein SbmA as being responsible for the observed resistance. These sbmA mutants were as fit as the wild-type parental strain as measured by growth rates in culture medium and mice and by long-term survival in stationary phase. These results suggest that resistance to certain antimicrobial peptides can rapidly develop without an obvious fitness cost for the bacteria and that resistance development could become a threat to the efficacy of antimicrobial peptides if used in a clinical setting.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Tetracycline, 98.0-102.0% (HPLC)
Supelco
Nitrofurantoin, VETRANAL®, analytical standard
Sigma-Aldrich
Nitrofurantoin, 98.0-102.0% (EP, UV), meets EP testing specifications
Sigma-Aldrich
Ampicillin, anhydrous, 96.0-102.0% (anhydrous basis)
Supelco
Ciprofloxacin, VETRANAL®, analytical standard
Sigma-Aldrich
Ciprofloxacin, ≥98% (HPLC)
Sigma-Aldrich
Nalidixic acid, ≥98%